Business Context and Reporting Period
Company: United-Guardian, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: United-Guardian is a Delaware corporation engaged in the research, development, manufacturing, and marketing of cosmetic ingredients, personal care products, pharmaceuticals, and specialty industrial products. The company operates in a single business segment. Its two primary product lines, LUBRAJEL (cosmetic ingredients and medical lubricants) and RENACIDIN (urological pharmaceutical), accounted for approximately 96% of total revenue in 2009.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Net Sales | $13,276,984 | $12,292,147 |
| Net Income | $3,878,963 | $3,162,931 |
| Earnings Per Share (Basic & Diluted) | $0.78 | $0.64 |
| Operating Income | $5,344,249 | $4,182,072 |
| Cost of Sales Margin | 40.1% | 44.0% |
| Effective Tax Rate | ~32% | ~32% |
| Cash from Operations | $4,337,448 | $3,412,385 |
| Working Capital | $14,735,891 | $13,236,680 |
| Current Ratio | 6.0 to 1 | 6.2 to 1 |
| Total Assets | $18,716,292 | $17,283,623 |
| Total Liabilities | $3,058,681 | $2,577,328 |
Note: The company has no long-term debt or line of credit. Total liabilities consist primarily of current liabilities including dividends payable ($1,582,860) and accrued expenses.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by $984,837 (8.0%) compared to 2008. This was driven by price increases in personal care and pharmaceutical products and a 37.0% volume increase in non-pharmaceutical medical products.
- Product Mix Shifts:
- Personal Care: Revenue increased 1.5% due to price hikes, though volume decreased slightly. Sales to the largest marketing partner (ISP) rose 11.7%, while sales to five other partners in Western Europe dropped 28.1% due to economic downturns.
- Medical (Non-Pharmaceutical): Revenue surged 37.0% ($725,850 increase), primarily due to increased demand for radiation-resistant catheter lubricants (LUBRAJEL RR/RC) and a specific oral moisturizer product.
- Pharmaceuticals: Revenue increased 6.8% due to a combination of price increases and a 3.5% volume increase.
- Profitability: Operating income increased by $1,162,177 (27.8%). Cost of sales as a percentage of sales improved to 40.1% from 44.0%, largely due to lower raw material costs. Operating expenses decreased by 3.3% due to payroll reductions.
- Investment Income: Other income decreased by 18.4% due to lower interest rates on certificates of deposit and bonds.
- Dividends: The company declared total dividends of $2,967,863 in 2009 ($0.60 per share), compared to $2,720,542 in 2008 ($0.55 per share).
Guidance, Outlook, and Risks
- Outlook: Management expects 2010 R&D costs to be comparable to the last two fiscal years. The company believes its working capital is sufficient to support operations for the next fiscal year. Long-term liquidity depends on cash flow from profitable operations.
- Marketing Agreements: The exclusive marketing agreement with International Specialty Products Inc. (ISP), the company's largest partner, expired in December 2008. The company is negotiating a renewal but expects the arrangement to continue informally. Other international distributor agreements are also operating under expired or verbal terms.
- Customer Concentration: Two customers accounted for approximately 52% of 2009 revenues. One customer accounted for 54% of outstanding accounts receivable at year-end.
- Legal and Regulatory:
- SEC/FINRA Review: A review of trading activity from 2007 was concluded by FINRA and referred to the SEC. The SEC completed its review of the 2007 10-K and 2008 10-Qs in January 2009 with no further comments after the company filed an amendment.
- Pension Plan: The company is in the process of terminating its defined benefit pension plan. IRS approval is expected in 2010. The plan is currently underfunded by $108,892.
- Risks: Key risks include dependence on a small number of marketing partners, the expiration of key marketing contracts, economic downturns in Western Europe affecting demand, and the need for regulatory approvals for new pharmaceutical products.
Investor Verification Checklist
- Marketing Contract Renewal: Verify the status of the renewal negotiations with ISP, which represents a significant portion of revenue.
- Customer Concentration: Assess the financial stability of the two customers representing 52% of revenue and 54% of receivables.
- Pension Plan Termination: Monitor the timeline for IRS approval of the pension plan termination and potential cash outflows associated with the underfunded status ($108,892).
- Raw Material Costs: Confirm if the favorable raw material cost trends in 2009 are sustainable, as this significantly impacted the gross margin improvement.
- Foreign Sales Exposure: Review the impact of the Western European economic downturn on the 28.1% sales decline among non-ISP partners.